Editorial: Precision medicine for antithrombotic therapy in patients after percutaneous coronary interventions.
作者信息
Galli Mattia, Costa Francesco, Angiolillo Dominick J
机构信息
Department of Cardiology, Maria Cecilia Hospital, GVM Care & Research, Cotignola, Italy.
Department of Biomedical and Dental Sciences and Morphological and Functional Imaging, University of Messina, Messina, Italy.
出版信息
Front Cardiovasc Med. 2023 Mar 3;10:1162630. doi: 10.3389/fcvm.2023.1162630. eCollection 2023.
Abstract
摘要
相似文献
1
Editorial: Precision medicine for antithrombotic therapy in patients after percutaneous coronary interventions.社论：经皮冠状动脉介入治疗术后患者抗血栓治疗的精准医学
Front Cardiovasc Med. 2023 Mar 3;10:1162630. doi: 10.3389/fcvm.2023.1162630. eCollection 2023.
2
Antithrombotic Therapy in Patients With Atrial Fibrillation Treated With Oral Anticoagulation Undergoing Percutaneous Coronary Intervention: A North American Perspective-2018 Update.经皮冠状动脉介入治疗的口服抗凝治疗心房颤动患者的抗血栓治疗：北美视角-2018 年更新。
Circulation. 2018 Jul 31;138(5):527-536. doi: 10.1161/CIRCULATIONAHA.118.034722.
3
Antiplatelet Therapy in Patients Requiring Oral Anticoagulation and Undergoing Percutaneous Coronary Intervention.需要口服抗凝治疗并行经皮冠状动脉介入治疗的患者的抗血小板治疗。
Interv Cardiol Clin. 2024 Oct;13(4):527-541. doi: 10.1016/j.iccl.2024.07.001. Epub 2024 Aug 3.
4
Clinical impact of high platelet reactivity in patients with atrial fibrillation and concomitant percutaneous coronary intervention on dual or triple antithrombotic therapy.心房颤动合并经皮冠状动脉介入治疗患者血小板高反应性对双联或三联抗栓治疗的临床影响。
J Thromb Thrombolysis. 2023 May;55(4):667-679. doi: 10.1007/s11239-023-02784-z. Epub 2023 Mar 11.
5
The role of triple antithrombotic therapy in patients with atrial fibrillation undergoing percutaneous coronary intervention.经皮冠状动脉介入治疗的心房颤动患者中三联抗栓治疗的作用。
Prog Cardiovasc Dis. 2021 Nov-Dec;69:11-17. doi: 10.1016/j.pcad.2021.11.010. Epub 2021 Dec 6.
6
Anticoagulant and Antiplatelet Prescribing Patterns for Patients with Atrial Fibrillation after Percutaneous Coronary Intervention.经皮冠状动脉介入治疗后心房颤动患者的抗凝和抗血小板用药模式
Can J Hosp Pharm. 2016 Jul-Aug;69(4):280-5. doi: 10.4212/cjhp.v69i4.1574. Epub 2016 Aug 31.
7
Managing the Antithrombotic Therapy After Percutaneous Coronary Intervention in Patients on Oral Anticoagulation.口服抗凝治疗患者经皮冠状动脉介入术后的抗栓治疗管理
Interv Cardiol. 2015 Sep;10(3):139-141. doi: 10.15420/ICR.2015.10.03.139.
8
Antithrombotic therapy in patients with atrial fibrillation and acute coronary syndrome undergoing percutaneous coronary intervention; insights from a meta-analysis.抗栓治疗在经皮冠状动脉介入治疗的心房颤动合并急性冠状动脉综合征患者中的应用：一项荟萃分析的见解。
Coron Artery Dis. 2021 Jan;32(1):31-35. doi: 10.1097/MCA.0000000000000900.
9
Safety and Efficacy of Triple Therapy With Ticagrelor or Prasugrel Versus Clopidogrel After Percutaneous Coronary Intervention for ST-Elevation Myocardial Infarction.替格瑞洛或普拉格雷三联疗法与氯吡格雷用于 ST 段抬高型心肌梗死经皮冠状动脉介入治疗后的安全性和疗效。
J Cardiovasc Pharmacol Ther. 2021 Nov;26(6):625-629. doi: 10.1177/10742484211031436. Epub 2021 Jul 8.
10
Update on Antithrombotic Therapy after Percutaneous Coronary Intervention.经皮冠状动脉介入治疗后抗栓治疗的最新进展
Intern Med. 2020 Feb 1;59(3):311-321. doi: 10.2169/internalmedicine.3685-19. Epub 2019 Oct 7.
本文引用的文献
1
Bleeding Complications in Patients Undergoing Percutaneous Coronary Intervention.接受经皮冠状动脉介入治疗患者的出血并发症
Rev Cardiovasc Med. 2022 Aug 15;23(8):286. doi: 10.31083/j.rcm2308286. eCollection 2022 Aug.
2
Timing, Selection, Modulation, and Duration of P2Y Inhibitors for Patients With Acute Coronary Syndromes Undergoing PCI.接受经皮冠状动脉介入治疗的急性冠状动脉综合征患者使用P2Y抑制剂的时机、选择、调整及持续时间
JACC Cardiovasc Interv. 2023 Jan 9;16(1):1-18. doi: 10.1016/j.jcin.2022.10.023.
3
Dual antiplatelet therapy duration after percutaneous coronary intervention in high bleeding risk: a meta-analysis of randomized trials.高出血风险患者经皮冠状动脉介入治疗后双联抗血小板治疗的持续时间：一项随机试验的荟萃分析
Eur Heart J. 2023 Mar 14;44(11):954-968. doi: 10.1093/eurheartj/ehac706.
4
Dual antiplatelet therapy duration after percutaneous coronary intervention in patients with indication to oral anticoagulant therapy. A systematic review and meta-analysis of randomized controlled trials.口服抗凝治疗适应证患者经皮冠状动脉介入术后双重抗血小板治疗的持续时间。一项随机对照试验的系统评价和荟萃分析。
Eur Heart J Cardiovasc Pharmacother. 2023 Apr 10;9(3):220-230. doi: 10.1093/ehjcvp/pvac065.
5
Antithrombotic Therapy After Acute Coronary Syndromes or Percutaneous Coronary Interventions in East Asian Populations.东亚人群急性冠状动脉综合征或经皮冠状动脉介入治疗后的抗栓治疗
JACC Asia. 2022 Feb 15;2(1):1-18. doi: 10.1016/j.jacasi.2021.12.005. eCollection 2022 Feb.
6
De-escalation of antiplatelet therapy in acute coronary syndromes: Why, how and when?急性冠状动脉综合征中抗血小板治疗的降阶梯：为何、如何以及何时？
Front Cardiovasc Med. 2022 Aug 25;9:975969. doi: 10.3389/fcvm.2022.975969. eCollection 2022.
7
Impact of diabetes mellitus on the pharmacodynamic effects of prasugrel and ticagrelor after switching from clopidogrel in patients with coronary artery disease.糖尿病对冠心病患者氯吡格雷转换为普拉格雷和替格瑞洛后药效学影响。
J Thromb Thrombolysis. 2022 Oct;54(3):461-469. doi: 10.1007/s11239-022-02696-4. Epub 2022 Sep 1.
8
Precision medicine in interventional cardiology: implications for antiplatelet therapy in patients undergoing percutaneous coronary intervention.介入心脏病学中的精准医学：对行经皮冠状动脉介入治疗患者抗血小板治疗的影响。
Pharmacogenomics. 2022 Aug;23(13):723-737. doi: 10.2217/pgs-2022-0057. Epub 2022 Aug 8.
9
Great Debate: Triple antithrombotic therapy in patients with atrial fibrillation undergoing coronary stenting should be limited to 1 week.激烈辩论：房颤患者接受冠状动脉支架置入术时的三联抗栓治疗应限于1周。
Eur Heart J. 2022 Oct 7;43(37):3512-3527. doi: 10.1093/eurheartj/ehac294.
10
Antiplatelet therapy after percutaneous coronary intervention.经皮冠状动脉介入治疗后的抗血小板治疗。
EuroIntervention. 2022 Apr 1;17(17):e1371-e1396. doi: 10.4244/EIJ-D-21-00904.
Zotero 插件